The week in pharma: action, reaction and insight – week to May 19, 2023
By Barbara Obstoj-Cardwell. Editor
US biotech Sarepta Therapeutics won a narrow vote from a Food and drug Administration (FDA) advisory committee to grant accelerated approval for its Duchenne muscular dystrophy candidate SRP-9001 (delandistrogene moxeparvovec). On the M&A front, last Tuesday, the US Federal Trade Commission (FTC) announced that it has filed a lawsuit to prevent Amgen from acquiring fellow US biotech Horizon Therapeutics, citing monopoly concerns, especially with regard to Krystexxa and Tepezza. Research news included Roivant subsidiary Dermavant Sciences announcing positive Phase III results for its Vtama in severe atopic dermatitis, and Australia’s Immutep released positive Phase II data on its LAG-3 immunotherapy eftilagimod in lung cancer.
Approval beckons for Sarepta’ gene therapy
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze